T n~ prognosis for patients with medulloblastoma has remained much the same in the past 20 years. Most centers report a 5-year survival rate of approximately 40% to 50%. 1,3,4 These figures may be falsely high estimates of survival because patients who die prior to completing a full course of radiation therapy are usually eliminated from the data base.
The conventional therapy for medulloblastoma has also not changed markedly in the last 20 years. Surgery may consist of biopsy, or subtotal or gross total resection of the posterior fossa tumor. Usually within 2 to 4 weeks after operation, a course of neuraxis radiation therapy is begun, which should consist of 3500 to 4000 rads to the whole brain and spinal canal, and 5000 to 5500 rads to the posterior fossa, administered in 150-to 200-rad fractions per day over a 6-to 8-week period. 1 Long-term effects on linear growth of the spinal column, 1~ intellectual development, 1l hematopoietic tissue, and neuroendocrine function 5 have been reported with this type of radiation therapy. The dose of radiation is frequently reduced by 25% to 33% in children under 2 years of age, because of the potential morbidity associated with it. There is a compelling reason to identify prognostic or risk factors that can be readily assessed at the time of diagnosis. Such knowledge can be used to triage patients into less aggressive treatment regimens for good-risk patients and more aggressive multimodal regimens for poor-risk patients. Several prognostic factors have been considered in the past for medulloblastoma, including age at diagnosis, size of the primary tumor, evidence of local tumor extension, s degree of surgical debulking, 7 and tumor histology/ If a good-risk population can be identified, it is reasonable to consider reducing the dose of neuraxis radiation therapy. If a poor-risk population can be identified, it seems justifiable to augment treatment.
We have performed a prospective study of 30 consecutive patients with primary malignant neuroectodermal tumors of the central nervous system (CNS) in an attempt to identify important prognostic factors at diagnosis. Each patient was evaluated before treatment to establish the extent of their disease.
Clinical Material and Methods
The study population consisted of 30 patients, with a mean age of 8.4 years, who were referred to Memorial Sloan-Kettering Cancer Center (MSKCC) for therapy after the initial diagnosis of tumor was established elsewhere ( Table 1) . All of the patients had a primary CNS tumor of neuroectodermal origin which could potentially disseminate throughout the CNS or body. Eleven different neurosurgeons had operated on the 30 patients. This study population is considered representative of a large metropolitan area with a broad range of ethnic, economic, and educational backgrounds.
Twenty-five patients had medulloblastomas, three had pineoblastomas, one had a primitive neuroecto- dermal tumor of the temporal lobe, and one had a malignant ependymoma (Table 1) . After review of tumor histopathology and completion of a physical and neurological examination, an evaluation of the extent of disease was undertaken for each patient. The evaluation consisted of four tests: postoperative computerized tomography (CT) scanning with and without contrast enhancement, myelography, usually several lumbar cerebrospinal fluid (CSF) cytological studies, and a bone marrow analysis. These tests were usually completed within 4 weeks of diagnosis. The patients were separated into two groups: patients in whom one or more tests indicated disseminated disease (Group 1), and patients in whom all four tests were normal (Group 2).
Results

Age and Survival Time
Eleven of the 30 patients (36%) had one or more abnormal tests (Group 1), and 19 patients (64%) had normal results in all four tests (Group 2). Group 1 patients were significantly younger than Group 2 patients (mean age 3.9 years versus 11 years, p < 0.01), and the median survival time for Group 1 patients was significantly shorter (p = 0.0002, Fig. 1 and Table 2 ). If medulloblastoma patients were con-sidered alone, Group 1 patients were also significantly younger (p < 0.01), and had a shorter survival time.
The patients in each group were separated into age categories from 0 to 5 years, 6 to 11 years, and over 11 years (Table 3 ). Nine of the 11 patients in Group 1 were 5 years of age or under. All eight patients who were aged 11 years or older had normal tests and thus fell into the good-risk group. Of the 14 patients aged 5 years or younger, nine (64%) had disseminated disease. ]-Mean age at diagnosis for these 11 patients was 3.9 years. 
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Evaluation of Extent of Disease
The results of the extent-of-disease evaluation in the 11 patients in Group 1 (Table 4) show that all patients had positive CSF cytological findings. Ten of these patients had other abnormal tests as well. Seven had three positive tests and three had two positive tests. One patient (Case 8), whose only positive test was CSF cytology, died of leptomeningeal seeding 11 months after diagnosis. In nine of the 11 patients with positive cytology, intradural extramedullary filling defects, consistent with subarachnoid metastases, were disclosed on myelography.
Extrinsic cells were detected in the bone marrow aspirate of two patients. This was an incidental finding in Case 2, but it was suspected in Case 9, a patient who presented with a high uric acid level. The bone scans were normal in both these individuals. Neither of these patients had preoperative placement of shunts. For these two patients, documentation of bone marrow seeding was critical in that systemic chemotherapy had been administered shortly after surgery. The patient in Case 9 died of Gram-negative septicemia during a period of chemotherapy-induced neutropenia. At autopsy, his bone marrow was free of tumor cells, and all gross tumor in the CNS had disappeared. The patient in Case 2 died of recurrent CNS disease 14 months after diagnosis. At autopsy, there was not evidence of systemic tumor.
Computerized tomography revealed dissemination beyond the tumor bed in six of the 11 patients in Group 1. The predominant pattern was diffuse subarachnoid spread (in four patients), although two had metastases only in the basal cisterns ( Table 5 ). The types of abnormalities detected on myelography (Table 6 ) included evidence of diffuse subarachnoid spread in the spinal canal in three patients. One patient had a 90% block in the upper thoracic region. Another had only filling defects in the upper cervical region, suggestive of local extension of a posterior fossa tumor. Another patient had isolated drop metastases in the sacral sac.
The CSF was obtained for analysis by lumbar puncture approximately 3 weeks after surgery ( Table  7) . The cell counts were usually abnormally high and, although malignant cells were detected in all specimens in Group I patients, the predominant cell type present was an inflammatory reactive cell. The CSF protein level was always abnormally high. The sugar content was abnormally low in three cases. A ventricular CSF specimen was available in only one case and was positive for malignant cells.
Treatment
It was appreciated early in this study that patients with disseminated disease at diagnosis (Group 1) were doing poorly, and most were offered a multimodal therapy protocol designed at our institution. This treatment consisted of preradiation chemotherapy followed by neuraxis radiation therapy over a 6-week period (5000 rads to the tumor bed, 3500 rads to the neuraxis, and 4500 rads to the major filling defects detected on myelography). Seven of the 11 Group 1 patients were treated with this protocol (Table 8) . Four Group 1 and 18 Group 2 patients were randomized on the Children's Cancer Study Group (CCSG) Protocol 942. 7 Thirteen patients received neuraxis irradiation alone, and nine received neuraxis radiation therapy and chemotherapy consisting of vincristine, prednisone, and l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU). Thus, there was a tendency to treat Group 1 patients more intensively. All patients with recurrent disease were offered systemic chemotherapy.
Of the six deaths in Group 1, two resulted from sepsis related to chemotherapy. Four other medulloblastoma patients died from recurrences outside the posterior fossa. The three deaths in Group 2 were all related to posterior fossa recurrences.
Fewer patients in Group 1 had received a complete gross total resection of the primary tumor than in Group 2 ( Table 9 ): Gross total resections were performed in two patients in Group 1 (18%) and in eight patients in Group 2 (42%). In part, the reluctance to perform radical operations in Group 1 patients reflected either known dissemination of disease prior to surgery or the operative finding of meningeal spread (six cases).
Discussion
Our prospective study clearly identifies two distinct but related prognostic factors in primary CNS neuroectodermal tumors of childhood: age and tumor dissemination at diagnosis. Younger children have a greater likelihood of having dissemination of disease at diagnosis, and patients with disseminated disease have a relatively poor prognosis for long-term survival. The median survival time was 12 months in Group 1, the group with disseminated disease at diagnosis. Thus, patients with localized disease at diagnosis tend to be older and have a much better prognosis.
Other authors have addressed these and other prognostic factors identifiable at the time of diagnosis in medulloblastoma. Harisiadis and Chang, 8 in a retrospective study of 59 medulloblastoma patients, identified two characteristic stages for newly diagnosed disease, a "T" or tumor size stage and an "M" or metastasis stage. Children with low "T" and "M" characteristics, that is, with small tumors that did not disseminate, had the best prognosis. In these cases, CSF cytologies were studied primarily because clinical indications were suggestive of metastasis. Unfortunately, because of the retrospective nature of the study, the results of CSF cytological studies were only available on one-third of the patients, and myelography was performed on only one patient. The "M" stage, therefore, was not thoroughly documented in all 59 patients. (None of our nine patients with abnormal myelograms had clinical evidence of myelopathy, and myelography would not have been clinically indicated.) The "T" stage was inferred from the neurosurgeons' and neuroradiologists' observations. Harisiadis and Chang also noted that younger patients had a poor prognosis; it is not clear whether this was related to the biology of the disease or was because the protocol was designed to undertreat children aged less than 3 years.
Deutch and Reigel ~ performed postsurgical myelography in 16 patients with medulloblastoma, seven (43%) of whom had abnormal myelograms. However, these authors could not correlate abnormal myelograms with either positive CSF cytology or poor prognosis. Five of the seven patients with abnormal myelograms had negative CSF cytological findings.
Two large cooperative pediatric oncology groups, the International Society of Pediatric Oncology (SLOP) z and the Children's Cancer Study Group (CCSG), 7 have amassed evidence identifying the importance of such prognostic factors as age, the "T" and "M" stages, and the degree of surgical resection. Data from the SlOP indicate that children under 2 years of age have the worst prognosis. Preliminary data gathered by the CCSG suggest a more favorable outcome with complete surgical resection of the primary tumor and a low "M" stage.
In our study, the two prognostic factors (young age and disease dissemination) were closely allied, in that nine of 14 children aged 5 years and under had disease dissemination, whereas none of the eight patients over 11 years exhibited dissemination. Two possible explanations for the association of age and disease dissemination are late diagnosis and tumor biology. Our data do not support the notion that the duration of symptoms prior to diagnosis was any longer in Group 1 patients than in Group 2; in fact, the opposite trend prevailed. The duration of preoperative symptoms was 6.5 _ 4.2 weeks (range 3 to 12 weeks) in Group 1 and 10.7 + 9.04 weeks (range 2 to 24 weeks) in Group 2.
There was a bias in therapy in the two groups. Early in our study, we suspected that children with disease dissemination had a relatively poor prognosis. Even though seven of the patients in Group 1 received an aggressive multimodal regimen consisting of chemotherapy followed by neuraxis radiation therapy, they still did poorly. However, two of the six children in Group I died of septicemia related to chemotherapy rather than from the disease itself. The four diseaserelated deaths were chiefly due to disseminated CNS tumor rather than to local disease. This is in contradistinction to the three patients in Group 2 whose deaths were related to local recurrence.
The CSF cytological examination revealed important information in our study. All patients in Group 1 had positive CSF cytological studies, and in 10 of the 11 cases other tests corroborated disease dissemi-nation. Therefore, positive cytological findings at 2 to 4 weeks after surgery reflected true disease dissemination rather than postoperative shedding of nonviable tumor cells. Since it is unlikely that an operation in a young child is more likely to disseminate tumor than in an older child, the tumor probably seeded the neuraxis prior to surgery, reflecting a higher degree of malignancy of disease in the younger patient. Further studies of the biology of medulloblastoma in young children should address the issue of predilection for early dissemination. The ideal method of distinguishing between the effects of tumor dissemination and age on survival would be to compare the survival rates of children under 5 years of age in Group 1 (nine patients) with those for children under 5 years of age in Group 2 (five patients). Although the numbers of patients are small, the Group 1 patients of this young age tended to do less well than the Group 2 patients.
Bone marrow aspiration at diagnosis is unique to our study. Although evidence of systemic medulloblastoma may be detected at the time of recurrence in as many as 35% of patients, 4 most of whom are symptomatic with bone pain, we discovered subclinical systemic metastases at diagnosis in two (7%) of our patients. Both patients were under 5 years of age. Since systemic medulloblastoma is very responsive to chemotherapy, it is especially important to perform bone marrow aspiration in younger patients?
The observations made in our prospective study have influenced the manner in which we manage our patients. Presently, with patients over 11 years of age, we initially perform only a postoperative CT scan and a CSF cytological examination. If both tests are negative, we do not order a myelogram. We feel optimistic about the child's outcome with neuraxis irradiation alone. The major concern will probably be the morbidity associated with therapy since the 5-year survival rate is probably greater than 70%. In such goodrisk patients, it would appear reasonable to reduce the dose of neuraxis irradiation in a future randomized study (for example, a reduction from 3500 to 4000 rads down to 2500 to 3000 rads) in an attempt to decrease morbidity. The posterior fossa dose should still exceed 5000 rads. ' A complete extent-of-disease evaluation is performed at our institution in every child under 5 years of age. If there is evidence of dissemination, then the prognosis with neuraxis irradiation alone is poor. These patients are presently managed with a multimodal institutional protocol involving chemotherapy and radiation therapy. A boost of radiation is added to areas of filling defects observed on myelography.
In conclusion, we defend the rationale for performing a battery of pre-therapy tests, including postoperative CT scanning, myelography, CSF cytology, and bone marrow aspiration in selected patients. The information derived will assist the clinician in the selection of individualized therapy as well as in a more accurate assessment of prognosis.
